See more : New Best Wire Industrial Co.,Ltd (5013.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Sangamo Therapeutics, Inc. (SGMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sangamo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Einhell Germany AG (EIN3.DE) Income Statement Analysis – Financial Results
- BowX Acquisition Corp. (BOWXU) Income Statement Analysis – Financial Results
- V-Mart Retail Limited (VMART.BO) Income Statement Analysis – Financial Results
- Adeia Inc. (ADEA) Income Statement Analysis – Financial Results
- Nippon Koshuha Steel Co.,Ltd. (5476.T) Income Statement Analysis – Financial Results
Sangamo Therapeutics, Inc. (SGMO)
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.23M | 111.30M | 110.70M | 118.19M | 102.43M | 84.45M | 36.57M | 19.39M | 39.54M | 45.87M | 24.13M | 21.66M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 3.43M | 2.20M | 2.04M | 1.15M | 632.00K |
| Cost of Revenue | 221.56M | 12.11M | 9.44M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.13M | 56.74M | 36.98M | 31.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.23M | -700.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -45.33M | 99.19M | 101.26M | -62.46M | -43.49M | -30.41M | -29.16M | -46.23M | -27.59M | -10.87M | -12.85M | -10.05M | 10.32M | 20.81M | 22.19M | 16.19M | 9.10M | 7.89M | 2.48M | 1.32M | 2.58M | 4.34M | 4.89M | 8.67M | 2.90M | 2.04M | 1.15M | 632.00K |
| Gross Profit Ratio | -25.72% | 89.12% | 91.47% | -52.84% | -42.46% | -36.01% | -79.75% | -238.43% | -69.78% | -23.71% | -53.23% | -46.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 252.40% | 131.82% | 100.00% | 100.00% | 100.00% |
| Research & Development | 234.06M | 249.90M | 230.82M | 180.65M | 145.92M | 114.87M | 65.73M | 65.62M | 67.20M | 56.74M | 36.98M | 31.71M | 32.10M | 33.15M | 28.98M | 31.23M | 25.56M | 21.53M | 11.42M | 11.05M | 10.19M | 13.36M | 15.51M | 11.35M | 4.30M | 4.26M | 1.70M | 628.00K |
| General & Administrative | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.26M | 3.59M | 4.16M | 4.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 663.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.17M | 62.68M | 63.22M | 67.10M | 61.69M | 46.74M | 27.20M | 26.33M | 19.20M | 15.68M | 13.80M | 12.14M | 14.04M | 12.59M | 12.61M | 10.33M | 8.31M | 7.09M | 4.51M | 4.92M | 3.59M | 4.16M | 4.75M | 4.57M | 1.80M | 1.24M | 797.00K | 322.00K |
| Other Expenses | 155.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 14.04M | 0.00 | 0.00 | 10.33M | 8.31M | 7.09M | 4.81M | 4.92M | 4.16M | 22.17M | 13.06M | 9.80M | 2.50M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 21.15M | 6.80M | 5.50M | 2.50M | 950.00K |
| Cost & Expenses | 450.24M | 312.58M | 294.04M | 247.74M | 207.61M | 161.60M | 92.93M | 91.95M | 86.40M | 72.42M | 50.78M | 43.85M | 46.14M | 45.74M | 41.59M | 41.56M | 33.87M | 28.61M | 16.23M | 15.97M | 14.35M | 35.54M | 20.26M | 15.92M | 6.10M | 5.50M | 2.50M | 950.00K |
| Interest Income | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.00K | 81.00K | 0.00 | 2.23M | 3.22M | 2.41M | 850.00K | 620.00K | 752.00K | 1.37M | 3.19M | 3.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.19M | 12.11M | 9.44M | 5.68M | 3.93M | 2.36M | 1.50M | 997.00K | 988.00K | 549.00K | 569.00K | 660.00K | 646.00K | 676.00K | 572.00K | 523.00K | -1.87M | -686.00K | 488.00K | 1.48M | 2.17M | 2.51M | 4.31M | 5.23M | 700.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.43M | -189.17M | -173.90M | -123.87M | -101.25M | -74.79M | -54.86M | -70.68M | -45.80M | -26.23M | -26.08M | -21.54M | -35.10M | -24.18M | -18.83M | -24.85M | -24.77M | -20.73M | -13.26M | -13.38M | -9.60M | -27.89M | -11.07M | -7.25M | -3.20M | -3.46M | -1.35M | -318.00K |
| EBITDA Ratio | -49.61% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -57.38% | -110.16% | -102.51% | -347.14% | -119.85% | -86.08% | -146.39% | -273.08% | -268.65% | -505.80% | -1,017.64% | -372.82% | -247.18% | 40.80% | -211.21% | -145.45% | -169.68% | -116.75% | -50.32% |
| Operating Income | -274.01M | -201.28M | -183.34M | -129.55M | -105.18M | -77.15M | -56.36M | -72.56M | -46.86M | -26.78M | -26.71M | -22.20M | -35.82M | -24.94M | -19.40M | -25.38M | -24.77M | -20.73M | -13.75M | -14.65M | -11.77M | -31.57M | -28.44M | -12.48M | -3.90M | -3.46M | -1.35M | -318.00K |
| Operating Income Ratio | -155.48% | -180.85% | -165.61% | -109.61% | -102.69% | -91.35% | -154.13% | -374.23% | -118.51% | -58.38% | -110.66% | -102.51% | -347.14% | -119.85% | -87.45% | -156.77% | -272.27% | -262.89% | -553.46% | -1,114.07% | -456.34% | -726.80% | -582.21% | -363.62% | -177.27% | -169.68% | -116.75% | -50.32% |
| Total Other Income/Expenses | 11.10M | 9.43M | 5.35M | 8.78M | 9.76M | 8.26M | 1.79M | 887.00K | 431.00K | 364.00K | 82.00K | -66.00K | 71.00K | 81.00K | 815.00K | 1.07M | 3.29M | 2.87M | 455.00K | 832.00K | 1.34M | 1.80M | 3.19M | 0.00 | 0.00 | 3.46M | 1.35M | 318.00K |
| Income Before Tax | -262.90M | -191.85M | -177.99M | -120.78M | -95.42M | -68.89M | -54.57M | -71.67M | -46.43M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -149.18% | -172.37% | -160.79% | -102.19% | -93.16% | -81.57% | -149.23% | -369.65% | -117.42% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.07M | 429.00K | 306.00K | 345.00K | -19.60M | 8.26M | -1.50M | -14.00K | -5.72M | -683.00K | -591.00K | -660.00K | -646.00K | -676.00K | -815.00K | -1.07M | -1.42M | -2.18M | -455.00K | -832.00K | -1.34M | -1.43M | 9.87M | -3.42M | -100.00K | 3.29M | 1.40M | 308.00K |
| Net Income | -257.83M | -192.28M | -178.30M | -121.12M | -75.82M | -68.33M | -54.57M | -71.66M | -40.70M | -26.42M | -26.62M | -22.26M | -35.75M | -24.85M | -18.59M | -24.30M | -21.48M | -17.86M | -13.29M | -13.82M | -10.43M | -29.76M | -25.25M | -9.07M | -3.80M | -3.29M | -1.40M | -308.00K |
| Net Income Ratio | -146.30% | -172.76% | -161.06% | -102.48% | -74.02% | -80.91% | -149.23% | -369.58% | -102.94% | -57.59% | -110.32% | -102.81% | -346.45% | -119.46% | -83.77% | -150.14% | -236.10% | -226.56% | -535.14% | -1,050.80% | -404.54% | -685.33% | -516.87% | -264.08% | -172.73% | -161.19% | -121.53% | -48.73% |
| EPS | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| EPS Diluted | -1.48 | -1.25 | -1.23 | -0.90 | -0.68 | -0.70 | -0.70 | -1.02 | -0.58 | -0.39 | -0.48 | -0.42 | -0.71 | -0.55 | -0.44 | -0.60 | -0.58 | -0.55 | -0.51 | -0.55 | -0.42 | -1.22 | -1.09 | -0.52 | -0.63 | -0.56 | -0.26 | -0.06 |
| Weighted Avg Shares Out | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
| Weighted Avg Shares Out (Dil) | 174.44M | 154.35M | 144.57M | 134.45M | 112.11M | 96.94M | 78.08M | 70.55M | 69.76M | 67.02M | 55.97M | 52.74M | 50.51M | 45.17M | 42.05M | 40.83M | 37.36M | 32.50M | 25.86M | 25.13M | 24.81M | 24.49M | 23.12M | 17.38M | 6.01M | 5.84M | 5.49M | 5.14M |
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports